Drugs for the treatment of refractory gout encompass a range of therapeutic options aimed at managing severe and persistent symptoms when standard treatments have proven insufficient. Biologic agents,such as interleukin inhibitors,play a crucial role by targeting inflammatory cytokines involved in the pathogenesis of gouty inflammation.Additionally,pegloticase,a recombinant uricase enzyme,is utilized to aggressively lower serum uric acid levels in refractory cases.

The global Drugs for the Treatment of Refractory Gout market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.

North American market for Drugs for the Treatment of Refractory Gout is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

Asia-Pacific market for Drugs for the Treatment of Refractory Gout is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

The major global manufacturers of Drugs for the Treatment of Refractory Gout include Roche, Biogen, Fresenius Kabi, Novartis, Sobi, Kiniksa Pharmaceuticals, Pfizer, Amgen, Horizon Therapeutics, Qilu Pharmaceutical, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Drugs for the Treatment of Refractory Gout, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Drugs for the Treatment of Refractory Gout.

The Drugs for the Treatment of Refractory Gout market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global Drugs for the Treatment of Refractory Gout market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Drugs for the Treatment of Refractory Gout manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Drugs for the Treatment of Refractory Gout Market Report

Report Metric	Details
Report Name	Drugs for the Treatment of Refractory Gout Market
Segment by Type	Interleukin Inhibitors Tumor Necrosis Factor Inhibitors PEGylated Recombinant Uricase Other
Segment by Application	Hospital and Clinic Retail Pharmacies Other
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	Roche, Biogen, Fresenius Kabi, Novartis, Sobi, Kiniksa Pharmaceuticals, Pfizer, Amgen, Horizon Therapeutics, Qilu Pharmaceutical, Hanwha Chemical, Bio-Thera Solutions, Zhuhai Livzon Biotechnology, Sandoz
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Drugs for the Treatment of Refractory Gout manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Drugs for the Treatment of Refractory Gout in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Drugs for the Treatment of Refractory Gout Market report?

Ans: The main players in the Drugs for the Treatment of Refractory Gout Market are Roche, Biogen, Fresenius Kabi, Novartis, Sobi, Kiniksa Pharmaceuticals, Pfizer, Amgen, Horizon Therapeutics, Qilu Pharmaceutical, Hanwha Chemical, Bio-Thera Solutions, Zhuhai Livzon Biotechnology, Sandoz

What are the Application segmentation covered in the Drugs for the Treatment of Refractory Gout Market report?

Ans: The Applications covered in the Drugs for the Treatment of Refractory Gout Market report are Hospital and Clinic, Retail Pharmacies, Other

What are the Type segmentation covered in the Drugs for the Treatment of Refractory Gout Market report?

Ans: The Types covered in the Drugs for the Treatment of Refractory Gout Market report are Interleukin Inhibitors, Tumor Necrosis Factor Inhibitors, PEGylated Recombinant Uricase, Other

1 Drugs for the Treatment of Refractory Gout Market Overview

1.1 Product Definition

1.2 Drugs for the Treatment of Refractory Gout by Type

1.2.1 Global Drugs for the Treatment of Refractory Gout Market Value Comparison by Type (2024-2030)

1.2.2 Interleukin Inhibitors

1.2.3 Tumor Necrosis Factor Inhibitors

1.2.4 PEGylated Recombinant Uricase

1.2.5 Other

1.3 Drugs for the Treatment of Refractory Gout by Application

1.3.1 Global Drugs for the Treatment of Refractory Gout Market Value by Application (2024-2030)

1.3.2 Hospital and Clinic

1.3.3 Retail Pharmacies

1.3.4 Other

1.4 Global Drugs for the Treatment of Refractory Gout Market Size Estimates and Forecasts

1.4.1 Global Drugs for the Treatment of Refractory Gout Revenue 2019-2030

1.4.2 Global Drugs for the Treatment of Refractory Gout Sales 2019-2030

1.4.3 Global Drugs for the Treatment of Refractory Gout Market Average Price (2019-2030)

1.5 Assumptions and Limitations

2 Drugs for the Treatment of Refractory Gout Market Competition by Manufacturers

2.1 Global Drugs for the Treatment of Refractory Gout Sales Market Share by Manufacturers (2019-2024)

2.2 Global Drugs for the Treatment of Refractory Gout Revenue Market Share by Manufacturers (2019-2024)

2.3 Global Drugs for the Treatment of Refractory Gout Average Price by Manufacturers (2019-2024)

2.4 Global Key Players of Drugs for the Treatment of Refractory Gout, Industry Ranking, 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of Drugs for the Treatment of Refractory Gout, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Drugs for the Treatment of Refractory Gout, Product Type & Application

2.7 Global Key Manufacturers of Drugs for the Treatment of Refractory Gout, Date of Enter into This Industry

2.8 Global Drugs for the Treatment of Refractory Gout Market Competitive Situation and Trends

2.8.1 Global Drugs for the Treatment of Refractory Gout Market Concentration Rate

2.8.2 The Global 5 and 10 Largest Drugs for the Treatment of Refractory Gout Players Market Share by Revenue

2.8.3 Global Drugs for the Treatment of Refractory Gout Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Global Drugs for the Treatment of Refractory Gout Market Scenario by Region

3.1 Global Drugs for the Treatment of Refractory Gout Market Size by Region: 2019 Versus 2023 Versus 2030

3.2 Global Drugs for the Treatment of Refractory Gout Sales by Region: 2019-2030

3.2.1 Global Drugs for the Treatment of Refractory Gout Sales by Region: 2019-2024

3.2.2 Global Drugs for the Treatment of Refractory Gout Sales by Region: 2025-2030

3.3 Global Drugs for the Treatment of Refractory Gout Revenue by Region: 2019-2030

3.3.1 Global Drugs for the Treatment of Refractory Gout Revenue by Region: 2019-2024

3.3.2 Global Drugs for the Treatment of Refractory Gout Revenue by Region: 2025-2030

3.4 North America Drugs for the Treatment of Refractory Gout Market Facts & Figures by Country

3.4.1 North America Drugs for the Treatment of Refractory Gout Market Size by Country: 2019 VS 2023 VS 2030

3.4.2 North America Drugs for the Treatment of Refractory Gout Sales by Country (2019-2030)

3.4.3 North America Drugs for the Treatment of Refractory Gout Revenue by Country (2019-2030)

3.4.4 United States

3.4.5 Canada

3.5 Europe Drugs for the Treatment of Refractory Gout Market Facts & Figures by Country

3.5.1 Europe Drugs for the Treatment of Refractory Gout Market Size by Country: 2019 VS 2023 VS 2030

3.5.2 Europe Drugs for the Treatment of Refractory Gout Sales by Country (2019-2030)

3.5.3 Europe Drugs for the Treatment of Refractory Gout Revenue by Country (2019-2030)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Drugs for the Treatment of Refractory Gout Market Facts & Figures by Region

3.6.1 Asia Pacific Drugs for the Treatment of Refractory Gout Market Size by Region: 2019 VS 2023 VS 2030

3.6.2 Asia Pacific Drugs for the Treatment of Refractory Gout Sales by Region (2019-2030)

3.6.3 Asia Pacific Drugs for the Treatment of Refractory Gout Revenue by Region (2019-2030)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 China Taiwan

3.6.10 Southeast Asia

3.7 Latin America Drugs for the Treatment of Refractory Gout Market Facts & Figures by Country

3.7.1 Latin America Drugs for the Treatment of Refractory Gout Market Size by Country: 2019 VS 2023 VS 2030

3.7.2 Latin America Drugs for the Treatment of Refractory Gout Sales by Country (2019-2030)

3.7.3 Latin America Drugs for the Treatment of Refractory Gout Revenue by Country

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.7.7 Colombia

3.8 Middle East and Africa Drugs for the Treatment of Refractory Gout Market Facts & Figures by Country

3.8.1 Middle East and Africa Drugs for the Treatment of Refractory Gout Market Size by Country: 2019 VS 2023 VS 2030

3.8.2 Middle East and Africa Drugs for the Treatment of Refractory Gout Sales by Country (2019-2030)

3.8.3 Middle East and Africa Drugs for the Treatment of Refractory Gout Revenue by Country

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4 Segment by Type

4.1 Global Drugs for the Treatment of Refractory Gout Sales by Type (2019-2030)

4.1.1 Global Drugs for the Treatment of Refractory Gout Sales by Type (2019-2024)

4.1.2 Global Drugs for the Treatment of Refractory Gout Sales by Type (2025-2030)

4.1.3 Global Drugs for the Treatment of Refractory Gout Sales Market Share by Type (2019-2030)

4.2 Global Drugs for the Treatment of Refractory Gout Revenue by Type (2019-2030)

4.2.1 Global Drugs for the Treatment of Refractory Gout Revenue by Type (2019-2024)

4.2.2 Global Drugs for the Treatment of Refractory Gout Revenue by Type (2025-2030)

4.2.3 Global Drugs for the Treatment of Refractory Gout Revenue Market Share by Type (2019-2030)

4.3 Global Drugs for the Treatment of Refractory Gout Price by Type (2019-2030)

5 Segment by Application

5.1 Global Drugs for the Treatment of Refractory Gout Sales by Application (2019-2030)

5.1.1 Global Drugs for the Treatment of Refractory Gout Sales by Application (2019-2024)

5.1.2 Global Drugs for the Treatment of Refractory Gout Sales by Application (2025-2030)

5.1.3 Global Drugs for the Treatment of Refractory Gout Sales Market Share by Application (2019-2030)

5.2 Global Drugs for the Treatment of Refractory Gout Revenue by Application (2019-2030)

5.2.1 Global Drugs for the Treatment of Refractory Gout Revenue by Application (2019-2024)

5.2.2 Global Drugs for the Treatment of Refractory Gout Revenue by Application (2025-2030)

5.2.3 Global Drugs for the Treatment of Refractory Gout Revenue Market Share by Application (2019-2030)

5.3 Global Drugs for the Treatment of Refractory Gout Price by Application (2019-2030)

6 Key Companies Profiled

6.1 Roche

6.1.1 Roche Company Information

6.1.2 Roche Description and Business Overview

6.1.3 Roche Drugs for the Treatment of Refractory Gout Sales, Revenue and Gross Margin (2019-2024)

6.1.4 Roche Drugs for the Treatment of Refractory Gout Product Portfolio

6.1.5 Roche Recent Developments/Updates

6.2 Biogen

6.2.1 Biogen Company Information

6.2.2 Biogen Description and Business Overview

6.2.3 Biogen Drugs for the Treatment of Refractory Gout Sales, Revenue and Gross Margin (2019-2024)

6.2.4 Biogen Drugs for the Treatment of Refractory Gout Product Portfolio

6.2.5 Biogen Recent Developments/Updates

6.3 Fresenius Kabi

6.3.1 Fresenius Kabi Company Information

6.3.2 Fresenius Kabi Description and Business Overview

6.3.3 Fresenius Kabi Drugs for the Treatment of Refractory Gout Sales, Revenue and Gross Margin (2019-2024)

6.3.4 Fresenius Kabi Drugs for the Treatment of Refractory Gout Product Portfolio

6.3.5 Fresenius Kabi Recent Developments/Updates

6.4 Novartis

6.4.1 Novartis Company Information

6.4.2 Novartis Description and Business Overview

6.4.3 Novartis Drugs for the Treatment of Refractory Gout Sales, Revenue and Gross Margin (2019-2024)

6.4.4 Novartis Drugs for the Treatment of Refractory Gout Product Portfolio

6.4.5 Novartis Recent Developments/Updates

6.5 Sobi

6.5.1 Sobi Company Information

6.5.2 Sobi Description and Business Overview

6.5.3 Sobi Drugs for the Treatment of Refractory Gout Sales, Revenue and Gross Margin (2019-2024)

6.5.4 Sobi Drugs for the Treatment of Refractory Gout Product Portfolio

6.5.5 Sobi Recent Developments/Updates

6.6 Kiniksa Pharmaceuticals

6.6.1 Kiniksa Pharmaceuticals Company Information

6.6.2 Kiniksa Pharmaceuticals Description and Business Overview

6.6.3 Kiniksa Pharmaceuticals Drugs for the Treatment of Refractory Gout Sales, Revenue and Gross Margin (2019-2024)

6.6.4 Kiniksa Pharmaceuticals Drugs for the Treatment of Refractory Gout Product Portfolio

6.6.5 Kiniksa Pharmaceuticals Recent Developments/Updates

6.7 Pfizer

6.7.1 Pfizer Company Information

6.7.2 Pfizer Description and Business Overview

6.7.3 Pfizer Drugs for the Treatment of Refractory Gout Sales, Revenue and Gross Margin (2019-2024)

6.7.4 Pfizer Drugs for the Treatment of Refractory Gout Product Portfolio

6.7.5 Pfizer Recent Developments/Updates

6.8 Amgen

6.8.1 Amgen Company Information

6.8.2 Amgen Description and Business Overview

6.8.3 Amgen Drugs for the Treatment of Refractory Gout Sales, Revenue and Gross Margin (2019-2024)

6.8.4 Amgen Drugs for the Treatment of Refractory Gout Product Portfolio

6.8.5 Amgen Recent Developments/Updates

6.9 Horizon Therapeutics

6.9.1 Horizon Therapeutics Company Information

6.9.2 Horizon Therapeutics Description and Business Overview

6.9.3 Horizon Therapeutics Drugs for the Treatment of Refractory Gout Sales, Revenue and Gross Margin (2019-2024)

6.9.4 Horizon Therapeutics Drugs for the Treatment of Refractory Gout Product Portfolio

6.9.5 Horizon Therapeutics Recent Developments/Updates

6.10 Qilu Pharmaceutical

6.10.1 Qilu Pharmaceutical Company Information

6.10.2 Qilu Pharmaceutical Description and Business Overview

6.10.3 Qilu Pharmaceutical Drugs for the Treatment of Refractory Gout Sales, Revenue and Gross Margin (2019-2024)

6.10.4 Qilu Pharmaceutical Drugs for the Treatment of Refractory Gout Product Portfolio

6.10.5 Qilu Pharmaceutical Recent Developments/Updates

6.11 Hanwha Chemical

6.11.1 Hanwha Chemical Company Information

6.11.2 Hanwha Chemical Description and Business Overview

6.11.3 Hanwha Chemical Drugs for the Treatment of Refractory Gout Sales, Revenue and Gross Margin (2019-2024)

6.11.4 Hanwha Chemical Drugs for the Treatment of Refractory Gout Product Portfolio

6.11.5 Hanwha Chemical Recent Developments/Updates

6.12 Bio-Thera Solutions

6.12.1 Bio-Thera Solutions Company Information

6.12.2 Bio-Thera Solutions Description and Business Overview

6.12.3 Bio-Thera Solutions Drugs for the Treatment of Refractory Gout Sales, Revenue and Gross Margin (2019-2024)

6.12.4 Bio-Thera Solutions Drugs for the Treatment of Refractory Gout Product Portfolio

6.12.5 Bio-Thera Solutions Recent Developments/Updates

6.13 Zhuhai Livzon Biotechnology

6.13.1 Zhuhai Livzon Biotechnology Company Information

6.13.2 Zhuhai Livzon Biotechnology Description and Business Overview

6.13.3 Zhuhai Livzon Biotechnology Drugs for the Treatment of Refractory Gout Sales, Revenue and Gross Margin (2019-2024)

6.13.4 Zhuhai Livzon Biotechnology Drugs for the Treatment of Refractory Gout Product Portfolio

6.13.5 Zhuhai Livzon Biotechnology Recent Developments/Updates

6.14 Sandoz

6.14.1 Sandoz Company Information

6.14.2 Sandoz Description and Business Overview

6.14.3 Sandoz Drugs for the Treatment of Refractory Gout Sales, Revenue and Gross Margin (2019-2024)

6.14.4 Sandoz Drugs for the Treatment of Refractory Gout Product Portfolio

6.14.5 Sandoz Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Drugs for the Treatment of Refractory Gout Industry Chain Analysis

7.2 Drugs for the Treatment of Refractory Gout Key Raw Materials

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Drugs for the Treatment of Refractory Gout Production Mode & Process

7.4 Drugs for the Treatment of Refractory Gout Sales and Marketing

7.4.1 Drugs for the Treatment of Refractory Gout Sales Channels

7.4.2 Drugs for the Treatment of Refractory Gout Distributors

7.5 Drugs for the Treatment of Refractory Gout Customers

8 Drugs for the Treatment of Refractory Gout Market Dynamics

8.1 Drugs for the Treatment of Refractory Gout Industry Trends

8.2 Drugs for the Treatment of Refractory Gout Market Drivers

8.3 Drugs for the Treatment of Refractory Gout Market Challenges

8.4 Drugs for the Treatment of Refractory Gout Market Restraints

9 Research Findings and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

Kiniksa Pharmaceuticals

Zhuhai Livzon Biotechnology

Sandoz Inc

List of Tables

Table 1. Global Drugs for the Treatment of Refractory Gout Market Value Comparison by Type (2024-2030) & (US$ Million)

Table 2. Global Drugs for the Treatment of Refractory Gout Market Value by Application (2024-2030) & (US$ Million)

Table 3. Global Drugs for the Treatment of Refractory Gout Market Competitive Situation by Manufacturers in 2023

Table 4. Global Drugs for the Treatment of Refractory Gout Sales (K Units) of Key Manufacturers (2019-2024)

Table 5. Global Drugs for the Treatment of Refractory Gout Sales Market Share by Manufacturers (2019-2024)

Table 6. Global Drugs for the Treatment of Refractory Gout Revenue (US$ Million) by Manufacturers (2019-2024)

Table 7. Global Drugs for the Treatment of Refractory Gout Revenue Share by Manufacturers (2019-2024)

Table 8. Global Market Drugs for the Treatment of Refractory Gout Average Price (US$/Unit) of Key Manufacturers (2019-2024)

Table 9. Global Key Players of Drugs for the Treatment of Refractory Gout, Industry Ranking, 2022 VS 2023 VS 2024

Table 10. Global Key Manufacturers of Drugs for the Treatment of Refractory Gout, Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of Drugs for the Treatment of Refractory Gout, Product Type & Application

Table 12. Global Key Manufacturers of Drugs for the Treatment of Refractory Gout, Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Drugs for the Treatment of Refractory Gout by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Drugs for the Treatment of Refractory Gout as of 2023)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global Drugs for the Treatment of Refractory Gout Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 17. Global Drugs for the Treatment of Refractory Gout Sales by Region (2019-2024) & (K Units)

Table 18. Global Drugs for the Treatment of Refractory Gout Sales Market Share by Region (2019-2024)

Table 19. Global Drugs for the Treatment of Refractory Gout Sales by Region (2025-2030) & (K Units)

Table 20. Global Drugs for the Treatment of Refractory Gout Sales Market Share by Region (2025-2030)

Table 21. Global Drugs for the Treatment of Refractory Gout Revenue by Region (2019-2024) & (US$ Million)

Table 22. Global Drugs for the Treatment of Refractory Gout Revenue Market Share by Region (2019-2024)

Table 23. Global Drugs for the Treatment of Refractory Gout Revenue by Region (2025-2030) & (US$ Million)

Table 24. Global Drugs for the Treatment of Refractory Gout Revenue Market Share by Region (2025-2030)

Table 25. North America Drugs for the Treatment of Refractory Gout Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 26. North America Drugs for the Treatment of Refractory Gout Sales by Country (2019-2024) & (K Units)

Table 27. North America Drugs for the Treatment of Refractory Gout Sales by Country (2025-2030) & (K Units)

Table 28. North America Drugs for the Treatment of Refractory Gout Revenue by Country (2019-2024) & (US$ Million)

Table 29. North America Drugs for the Treatment of Refractory Gout Revenue by Country (2025-2030) & (US$ Million)

Table 30. Europe Drugs for the Treatment of Refractory Gout Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 31. Europe Drugs for the Treatment of Refractory Gout Sales by Country (2019-2024) & (K Units)

Table 32. Europe Drugs for the Treatment of Refractory Gout Sales by Country (2025-2030) & (K Units)

Table 33. Europe Drugs for the Treatment of Refractory Gout Revenue by Country (2019-2024) & (US$ Million)

Table 34. Europe Drugs for the Treatment of Refractory Gout Revenue by Country (2025-2030) & (US$ Million)

Table 35. Asia Pacific Drugs for the Treatment of Refractory Gout Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 36. Asia Pacific Drugs for the Treatment of Refractory Gout Sales by Region (2019-2024) & (K Units)

Table 37. Asia Pacific Drugs for the Treatment of Refractory Gout Sales by Region (2025-2030) & (K Units)

Table 38. Asia Pacific Drugs for the Treatment of Refractory Gout Revenue by Region (2019-2024) & (US$ Million)

Table 39. Asia Pacific Drugs for the Treatment of Refractory Gout Revenue by Region (2025-2030) & (US$ Million)

Table 40. Latin America Drugs for the Treatment of Refractory Gout Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 41. Latin America Drugs for the Treatment of Refractory Gout Sales by Country (2019-2024) & (K Units)

Table 42. Latin America Drugs for the Treatment of Refractory Gout Sales by Country (2025-2030) & (K Units)

Table 43. Latin America Drugs for the Treatment of Refractory Gout Revenue by Country (2019-2024) & (US$ Million)

Table 44. Latin America Drugs for the Treatment of Refractory Gout Revenue Market Share by Country (2019-2024)

Table 45. Middle East and Africa Drugs for the Treatment of Refractory Gout Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 46. Middle East and Africa Drugs for the Treatment of Refractory Gout Sales by Country (2019-2024) & (K Units)

Table 47. Middle East and Africa Drugs for the Treatment of Refractory Gout Sales by Country (2025-2030) & (K Units)

Table 48. Middle East and Africa Drugs for the Treatment of Refractory Gout Revenue by Country (2019-2024) & (US$ Million)

Table 49. Middle East and Africa Drugs for the Treatment of Refractory Gout Revenue by Country (2025-2030) & (US$ Million)

Table 50. Global Drugs for the Treatment of Refractory Gout Sales (K Units) by Type (2019-2024)

Table 51. Global Drugs for the Treatment of Refractory Gout Sales (K Units) by Type (2025-2030)

Table 52. Global Drugs for the Treatment of Refractory Gout Sales Market Share by Type (2019-2024)

Table 53. Global Drugs for the Treatment of Refractory Gout Sales Market Share by Type (2025-2030)

Table 54. Global Drugs for the Treatment of Refractory Gout Revenue (US$ Million) by Type (2019-2024)

Table 55. Global Drugs for the Treatment of Refractory Gout Revenue (US$ Million) by Type (2025-2030)

Table 56. Global Drugs for the Treatment of Refractory Gout Revenue Market Share by Type (2019-2024)

Table 57. Global Drugs for the Treatment of Refractory Gout Revenue Market Share by Type (2025-2030)

Table 58. Global Drugs for the Treatment of Refractory Gout Price (US$/Unit) by Type (2019-2024)

Table 59. Global Drugs for the Treatment of Refractory Gout Price (US$/Unit) by Type (2025-2030)

Table 60. Global Drugs for the Treatment of Refractory Gout Sales (K Units) by Application (2019-2024)

Table 61. Global Drugs for the Treatment of Refractory Gout Sales (K Units) by Application (2025-2030)

Table 62. Global Drugs for the Treatment of Refractory Gout Sales Market Share by Application (2019-2024)

Table 63. Global Drugs for the Treatment of Refractory Gout Sales Market Share by Application (2025-2030)

Table 64. Global Drugs for the Treatment of Refractory Gout Revenue (US$ Million) by Application (2019-2024)

Table 65. Global Drugs for the Treatment of Refractory Gout Revenue (US$ Million) by Application (2025-2030)

Table 66. Global Drugs for the Treatment of Refractory Gout Revenue Market Share by Application (2019-2024)

Table 67. Global Drugs for the Treatment of Refractory Gout Revenue Market Share by Application (2025-2030)

Table 68. Global Drugs for the Treatment of Refractory Gout Price (US$/Unit) by Application (2019-2024)

Table 69. Global Drugs for the Treatment of Refractory Gout Price (US$/Unit) by Application (2025-2030)

Table 70. Roche Company Information

Table 71. Roche Description and Business Overview

Table 72. Roche Drugs for the Treatment of Refractory Gout Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 73. Roche Drugs for the Treatment of Refractory Gout Product

Table 74. Roche Recent Developments/Updates

Table 75. Biogen Company Information

Table 76. Biogen Description and Business Overview

Table 77. Biogen Drugs for the Treatment of Refractory Gout Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 78. Biogen Drugs for the Treatment of Refractory Gout Product

Table 79. Biogen Recent Developments/Updates

Table 80. Fresenius Kabi Company Information

Table 81. Fresenius Kabi Description and Business Overview

Table 82. Fresenius Kabi Drugs for the Treatment of Refractory Gout Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 83. Fresenius Kabi Drugs for the Treatment of Refractory Gout Product

Table 84. Fresenius Kabi Recent Developments/Updates

Table 85. Novartis Company Information

Table 86. Novartis Description and Business Overview

Table 87. Novartis Drugs for the Treatment of Refractory Gout Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 88. Novartis Drugs for the Treatment of Refractory Gout Product

Table 89. Novartis Recent Developments/Updates

Table 90. Sobi Company Information

Table 91. Sobi Description and Business Overview

Table 92. Sobi Drugs for the Treatment of Refractory Gout Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 93. Sobi Drugs for the Treatment of Refractory Gout Product

Table 94. Sobi Recent Developments/Updates

Table 95. Kiniksa Pharmaceuticals Company Information

Table 96. Kiniksa Pharmaceuticals Description and Business Overview

Table 97. Kiniksa Pharmaceuticals Drugs for the Treatment of Refractory Gout Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 98. Kiniksa Pharmaceuticals Drugs for the Treatment of Refractory Gout Product

Table 99. Kiniksa Pharmaceuticals Recent Developments/Updates

Table 100. Pfizer Company Information

Table 101. Pfizer Description and Business Overview

Table 102. Pfizer Drugs for the Treatment of Refractory Gout Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 103. Pfizer Drugs for the Treatment of Refractory Gout Product

Table 104. Pfizer Recent Developments/Updates

Table 105. Amgen Company Information

Table 106. Amgen Description and Business Overview

Table 107. Amgen Drugs for the Treatment of Refractory Gout Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 108. Amgen Drugs for the Treatment of Refractory Gout Product

Table 109. Amgen Recent Developments/Updates

Table 110. Horizon Therapeutics Company Information

Table 111. Horizon Therapeutics Description and Business Overview

Table 112. Horizon Therapeutics Drugs for the Treatment of Refractory Gout Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 113. Horizon Therapeutics Drugs for the Treatment of Refractory Gout Product

Table 114. Horizon Therapeutics Recent Developments/Updates

Table 115. Qilu Pharmaceutical Company Information

Table 116. Qilu Pharmaceutical Description and Business Overview

Table 117. Qilu Pharmaceutical Drugs for the Treatment of Refractory Gout Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 118. Qilu Pharmaceutical Drugs for the Treatment of Refractory Gout Product

Table 119. Qilu Pharmaceutical Recent Developments/Updates

Table 120. Hanwha Chemical Company Information

Table 121. Hanwha Chemical Description and Business Overview

Table 122. Hanwha Chemical Drugs for the Treatment of Refractory Gout Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 123. Hanwha Chemical Drugs for the Treatment of Refractory Gout Product

Table 124. Hanwha Chemical Recent Developments/Updates

Table 125. Bio-Thera Solutions Company Information

Table 126. Bio-Thera Solutions Description and Business Overview

Table 127. Bio-Thera Solutions Drugs for the Treatment of Refractory Gout Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 128. Bio-Thera Solutions Drugs for the Treatment of Refractory Gout Product

Table 129. Bio-Thera Solutions Recent Developments/Updates

Table 130. Zhuhai Livzon Biotechnology Company Information

Table 131. Zhuhai Livzon Biotechnology Description and Business Overview

Table 132. Zhuhai Livzon Biotechnology Drugs for the Treatment of Refractory Gout Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 133. Zhuhai Livzon Biotechnology Drugs for the Treatment of Refractory Gout Product

Table 134. Zhuhai Livzon Biotechnology Recent Developments/Updates

Table 135. Sandoz Company Information

Table 136. Sandoz Description and Business Overview

Table 137. Sandoz Drugs for the Treatment of Refractory Gout Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 138. Sandoz Drugs for the Treatment of Refractory Gout Product

Table 139. Sandoz Recent Developments/Updates

Table 140. Key Raw Materials Lists

Table 141. Raw Materials Key Suppliers Lists

Table 142. Drugs for the Treatment of Refractory Gout Distributors List

Table 143. Drugs for the Treatment of Refractory Gout Customers List

Table 144. Drugs for the Treatment of Refractory Gout Market Trends

Table 145. Drugs for the Treatment of Refractory Gout Market Drivers

Table 146. Drugs for the Treatment of Refractory Gout Market Challenges

Table 147. Drugs for the Treatment of Refractory Gout Market Restraints

Table 148. Research Programs/Design for This Report

Table 149. Key Data Information from Secondary Sources

Table 150. Key Data Information from Primary Sources

Table 151. Authors List of This Report

List of Figures

Figure 1. Product Picture of Drugs for the Treatment of Refractory Gout

Figure 2. Global Drugs for the Treatment of Refractory Gout Market Value Comparison by Type (2024-2030) & (US$ Million)

Figure 3. Global Drugs for the Treatment of Refractory Gout Market Share by Type: 2023 & 2030

Figure 4. Interleukin Inhibitors Product Picture

Figure 5. Tumor Necrosis Factor Inhibitors Product Picture

Figure 6. PEGylated Recombinant Uricase Product Picture

Figure 7. Other Product Picture

Figure 8. Global Drugs for the Treatment of Refractory Gout Market Value by Application (2024-2030) & (US$ Million)

Figure 9. Global Drugs for the Treatment of Refractory Gout Market Share by Application: 2023 & 2030

Figure 10. Hospital and Clinic

Figure 11. Retail Pharmacies

Figure 12. Other

Figure 13. Global Drugs for the Treatment of Refractory Gout Revenue, (US$ Million), 2019 VS 2023 VS 2030

Figure 14. Global Drugs for the Treatment of Refractory Gout Market Size (2019-2030) & (US$ Million)

Figure 15. Global Drugs for the Treatment of Refractory Gout Sales (2019-2030) & (K Units)

Figure 16. Global Drugs for the Treatment of Refractory Gout Average Price (US$/Unit) & (2019-2030)

Figure 17. Drugs for the Treatment of Refractory Gout Report Years Considered

Figure 18. Drugs for the Treatment of Refractory Gout Sales Share by Manufacturers in 2023

Figure 19. Global Drugs for the Treatment of Refractory Gout Revenue Share by Manufacturers in 2023

Figure 20. Global 5 and 10 Largest Drugs for the Treatment of Refractory Gout Players: Market Share by Revenue in Drugs for the Treatment of Refractory Gout in 2023

Figure 21. Drugs for the Treatment of Refractory Gout Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023

Figure 22. Global Drugs for the Treatment of Refractory Gout Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Figure 23. North America Drugs for the Treatment of Refractory Gout Sales Market Share by Country (2019-2030)

Figure 24. North America Drugs for the Treatment of Refractory Gout Revenue Market Share by Country (2019-2030)

Figure 25. United States Drugs for the Treatment of Refractory Gout Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 26. Canada Drugs for the Treatment of Refractory Gout Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 27. Europe Drugs for the Treatment of Refractory Gout Sales Market Share by Country (2019-2030)

Figure 28. Europe Drugs for the Treatment of Refractory Gout Revenue Market Share by Country (2019-2030)

Figure 29. Germany Drugs for the Treatment of Refractory Gout Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 30. France Drugs for the Treatment of Refractory Gout Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 31. U.K. Drugs for the Treatment of Refractory Gout Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 32. Italy Drugs for the Treatment of Refractory Gout Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 33. Russia Drugs for the Treatment of Refractory Gout Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 34. Asia Pacific Drugs for the Treatment of Refractory Gout Sales Market Share by Region (2019-2030)

Figure 35. Asia Pacific Drugs for the Treatment of Refractory Gout Revenue Market Share by Region (2019-2030)

Figure 36. China Drugs for the Treatment of Refractory Gout Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 37. Japan Drugs for the Treatment of Refractory Gout Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 38. South Korea Drugs for the Treatment of Refractory Gout Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 39. India Drugs for the Treatment of Refractory Gout Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 40. Australia Drugs for the Treatment of Refractory Gout Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 41. China Taiwan Drugs for the Treatment of Refractory Gout Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 42. Southeast Asia Drugs for the Treatment of Refractory Gout Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 43. Latin America Drugs for the Treatment of Refractory Gout Sales Market Share by Country (2019-2030)

Figure 44. Mexico Drugs for the Treatment of Refractory Gout Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 45. Brazil Drugs for the Treatment of Refractory Gout Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 46. Argentina Drugs for the Treatment of Refractory Gout Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 47. Colombia Drugs for the Treatment of Refractory Gout Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 48. Middle East and Africa Drugs for the Treatment of Refractory Gout Sales Market Share by Country (2019-2030)

Figure 49. Middle East and Africa Drugs for the Treatment of Refractory Gout Revenue Market Share by Country (2019-2030)

Figure 50. Turkey Drugs for the Treatment of Refractory Gout Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 51. Saudi Arabia Drugs for the Treatment of Refractory Gout Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 52. UAE Drugs for the Treatment of Refractory Gout Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 53. Global Sales Market Share of Drugs for the Treatment of Refractory Gout by Type (2019-2030)

Figure 54. Global Revenue Market Share of Drugs for the Treatment of Refractory Gout by Type (2019-2030)

Figure 55. Global Drugs for the Treatment of Refractory Gout Price (US$/Unit) by Type (2019-2030)

Figure 56. Global Sales Market Share of Drugs for the Treatment of Refractory Gout by Application (2019-2030)

Figure 57. Global Revenue Market Share of Drugs for the Treatment of Refractory Gout by Application (2019-2030)

Figure 58. Global Drugs for the Treatment of Refractory Gout Price (US$/Unit) by Application (2019-2030)

Figure 59. Drugs for the Treatment of Refractory Gout Value Chain

Figure 60. Drugs for the Treatment of Refractory Gout Production Process

Figure 61. Channels of Distribution (Direct Vs Distribution)

Figure 62. Bottom-up and Top-down Approaches for This Report

Figure 63. Data Triangulation

Figure 64. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

120 Pages

Type: Report

Code: QYRE-Auto-6F3327

Wed Nov 27 00:00:00 UTC 2024

Add to Cart

Rheumatoid Arthritis Diagnostic Tests - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

120 Pages

Type: Report

Code: QYRE-Auto-29N5788

Wed Nov 27 00:00:00 UTC 2024

Add to Cart

Global Juvenile Idiopathic Arthritis Diagnostic Market Research Report 2024

120 Pages

Type: Report

Code: QYRE-Auto-19E18521

Thu Nov 21 00:00:00 UTC 2024

Add to Cart

Ankle Arthritis Treatment - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

120 Pages

Type: Report

Code: QYRE-Auto-12V5643

Tue Nov 12 00:00:00 UTC 2024

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions

Global Drugs for the Treatment of Refractory Gout Market Research Report 2024

Published Date: August 2024

Report Code: QYRE-Auto-4A18202

Global Drugs for the Treatment of Refractory Gout Market Research Report 2024

FEATURED COMPANIES

Drugs for the Treatment of Refractory Gout Market

Report Scope

Scope of Drugs for the Treatment of Refractory Gout Market Report

Core Chapters

FAQ for this report

Who are the main players in the Drugs for the Treatment of Refractory Gout Market report?

What are the Application segmentation covered in the Drugs for the Treatment of Refractory Gout Market report?

What are the Type segmentation covered in the Drugs for the Treatment of Refractory Gout Market report?

FEATURED COMPANIES

RELATED REPORTS